ASSESSING PARTITIONED SURVIVAL MODEL IN CANCER TREATMENT EVALUATION IN FRANCE

被引：0
|
作者：
Eymere, S. [1 ]
Cabout, E. [1 ]
Launois, R. [1 ]
机构：
[1] REES France, Paris, France
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN248
引用
收藏
页码：S467 / S467
页数：1
相关论文
共 50 条
  • [1] AN ECONOMIC EVALUATION OF NIVOLUMAB COMPARED WITH DOCETAXEL AS THE SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED NSCLC IN CHINA USING MARKOV MODEL AND PARTITIONED SURVIVAL MODEL
    Yao, J.
    Shao, R.
    Guan, X.
    Zhang, Y.
    Li, H.
    [J]. VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [2] Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments
    Rui, Mingjun
    Wang, Yingcheng
    Fei, Zhengyang
    Zhang, Xueke
    Shang, Ye
    Li, Hongchao
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 373 - 380
  • [3] Survival of women with breast cancer in France: variation with age, stage and treatment
    Pascale Grosclaude
    Marc Colonna
    Guy Hedelin
    Brigitte Tretarre
    Patrick Arveux
    Josette Mace Lesec'h
    Nicole Raverdy
    Martine Sauvage-Machelard
    [J]. Breast Cancer Research and Treatment, 2001, 70 : 137 - 143
  • [4] Adolescent cancer survival in France
    Brugieres, L.
    Desandes, E.
    Lacour, B.
    Sommelet, D.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 279 - 280
  • [5] Survival of women with breast cancer in France: variation with age, stage and treatment
    Grosclaude, P
    Colonna, M
    Hedelin, G
    Tretarre, B
    Arveux, P
    Lesec'h, JM
    Raverdy, N
    Sauvage-Machelard, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 70 (02) : 137 - 143
  • [6] COMPETING RISK AND MULTISTATE MODEL COMPARED TO PARTITIONED SURVIVAL MODEL IN METASTATIC NON-SMALL CELL LUNG CANCER
    Le Mezo, A.
    Kandel, M.
    Caillon, M.
    Chauny, J., V
    Borget, I
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S11 - S11
  • [7] SURVIVAL TIME ANALYSIS FOR TREATMENT EVALUATION IN CANCER THERAPY
    KODLIN, D
    [J]. CANCER RESEARCH, 1961, 21 (09) : 1103 - &
  • [8] Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model
    Rui, Mingjun
    Shi, Fenghao
    Shang, Ye
    Meng, Rui
    Li, Hongchao
    [J]. ADVANCES IN THERAPY, 2020, 37 (09) : 3761 - 3774
  • [9] Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model
    Mingjun Rui
    Fenghao Shi
    Ye Shang
    Rui Meng
    Hongchao Li
    [J]. Advances in Therapy, 2020, 37 : 3761 - 3774
  • [10] THE INHERENT BIAS FROM USING PARTITIONED SURVIVAL MODELS IN ECONOMIC EVALUATION
    Coyle, D.
    Coyle, K.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A194 - A194
12345